Skip to product information
1 of 1

  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Armani Acqua Di Gio Profondo EDP 125ml

Armani Acqua Di Gio Profondo EDP 125ml

  • Ozempic®️-equivalent therapy now available for weight management
  • Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • May help reduce osteoarthritis-related pain
  • Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • Supports cardiovascular risk reduction
  • Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £100.00
Sale price £100.00
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details
Armani Acqua Di Giò Profondo Eau de Parfum 125ml The bold reinterpretation of Acqua Di Giò by Armani presents itself through Armani Acqua Di Giò Profondo which offers a 125ml Eau de Parfum. The 125ml Eau de Parfum unites oceanic power with refined masculine elements to express the essence of liberty and exploration and natural connection. Master perfumer Alberto Morillas created Profondo which begins with oceanic scents and green mandarin notes that mimic ocean spray freshness. The heart of Profondo contains refined depth through aromatic rosemary and lavender and cypress notes which are supported by patchouli and musk and mineral amber in its base. The deep blue glass bottle of Profondo contains more than a fragrance because it leads you through a journey to discover your inner essence. Fragrance Family: Aromatic Aquatic Top Notes: Marine Notes, Green Mandarin, Bergamot Heart Notes: Rosemary, Lavender, Cypress, Mastic Base Notes: Patchouli, Musk, Mineral Amber, Incense The modern man who seeks intense authenticity and elegance will find this fragrance suitable for his needs.

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2088658
Muzammil Peerally

Authored by:

Muzammil Peerally

Superintendent Pharmacist

GPhC Number: 2232689
Tarun Kumar

Reviewed by:

Tarun Kumar

Clinical Leads

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities